Amrutanjan Healt

The Balm That Outlived Its Buyers

Walk into almost any Indian home older than forty years and open the small tin cupboard above the kitchen shelf — you will likely find a squat yellow pot of Amrutanjan. It has been there since a headache in 1950, and it will probably outlive whoever bought it. A company that has been rubbing away migraines and cold-blocked noses since 1893, now run by the third generation of the same family, is not a startup story. It is a habit business. And today the market is offering that habit at a price it rarely sees.

Think of Amrutanjan the way you'd think of the neighbourhood chemist your family has trusted for decades — nothing flashy, no big new product every quarter, but you keep going back, and so does everyone on the street. The company sells pain balm, women's hygiene products under Comfy, and fruit juice drinks under Fruitnik. Three shelves, one shopper's trust.

Why the Screen Coughed It Up Now

Here is the plain arithmetic that makes this a *short-term* candidate rather than a forever-holding. The stock trades at a P/E of 23.2. Over the last five years its own median P/E has been 41, and over ten years, 41.4. So you are being asked to pay a little over half of what buyers have historically paid for the same rupee of Amrutanjan's earnings — roughly a 43% discount to its five-year normal and a 44% discount to its ten-year normal.

The market did not hand out this discount for free. The share price is at ₹498, a whisker above its 52-week low of ₹483 and a long way down from ₹791 at the top. It has fallen 31% in the past year and has actually gone *backwards* at 6-7% a year over three and five years. The crowd fell out of love, and the P/E collapsed with it.

The question a short-term buyer must ask is simple: is the business broken, or just the mood around it? Look at what the company itself did while the price fell. Sales climbed from ₹421 crore in FY24 to ₹452 crore in FY25, and the trailing twelve months now read ₹511 crore. Profit went from ₹45 crore to ₹51 crore, with TTM at ₹54 crore. The kitchen cupboard is still being restocked. The stock simply de-rated faster than the business slowed.

The Ledger — Clean, But Not a Racehorse

Two things I want you to hold onto, because they anchor the whole case. First, dilution — there has been none. The equity capital has sat at ₹3 crore, unmoved, for eleven straight years, Mar 2015 through Mar 2026. No secret share issuance quietly shrinking your slice while management smiles at the AGM. Whatever these profits are, they are split among the same number of hands as a decade ago. For a value buyer that flat line is worth more than a page of promises.

Second, and here honesty demands the opposite tone — the growth is modest, and one number is genuinely weak. Sales have compounded at about 11% over ten years and just 9% over five. That is respectable, not thrilling. But profit growth over five years is a limp 1% — earnings essentially went nowhere between the Covid-era spike of FY21-22 and now, because that ₹61-67 crore profit burst simply did not repeat. The recent three-year profit figure of 17% is really a recovery off a dip, not a new engine. Do not walk in expecting a compounder; walk in expecting a good business bought cheap.

The balance sheet is where Amrutanjan earns respect. It is almost debt-free. Return on capital sits at 24.8% and return on equity at 18.5% — the business turns its money over well without borrowing to do it. Working capital days have tightened from 123 to 96. And it pays you to wait: a dividend yield near 1%, backed by a steady 26.7% payout, on a business that isn't burning cash.

The Thing I'd Watch Before I'd Cheer

One flag I will not paper over — promoters have been trimming. Their stake has slipped from 50.59% to 46.52% over recent quarters, a 3.5-point reduction. When the family that has run a firm for 130 years sells down while the stock is falling, you owe yourself an explanation before you fall in love. It may be routine estate or diversification, but it is not a signal to ignore. Note, though, that domestic institutions bought what promoters and public sold — DII holding nearly doubled to 12.29%. Someone with a spreadsheet decided this de-rating was overdone.

The Wager, Stated Plainly

This is not a story of a business rocketing higher. It is a story of a durable, cash-generative, debt-free 130-year-old brand whose valuation fell far below its own long-run average while its sales and profits kept quietly rising. At a P/E of 23 against a decade-median of 41, the short-term bet is that the mood, not the mechanics, was mispriced — and that a stock sitting on its 52-week floor has more room to mean-revert than to fall.

Buy it for the gap between price and history, size it as a trade not a marriage, and keep the promoter selling in the corner of your eye the whole way.